The IN2COVID Study is a 2-staged phase I/II double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of AP-003 (Interferon α2b) when administered via inhalation twice daily for 10 days. Participants will have a final visit at Day 11.
A lead-in phase 1 substudy will be performed with at least 18 healthy adult male subjects to assess safety and tolerability of inhaled AP-003 compared to placebo for 10 days. Two cohorts of 9 subjects will be randomly assigned to receive two doses of inhaled AP-003 or placebo with an allocation ratio of 2:1. The first cohort will assess a dose of 2.5 MIU of inhaled AP-003. If no adverse events are observed, the second cohort will be conducted using a dose of 5 MIU of inhaled AP-003. Maximum tolerated dose will be determined in this phase 1 substudy.
After the completion of phase 1, the study will continue with a phase 2 treatment RCT in patients with COVID-19. In this phase, 150 adults with mild or moderate COVID-19 demonstrated by SARS-CoV-2 positive polymerase chain reaction (PCR) ≤ 5 days at enrollment will be randomized 1:1 (75 in each arm) to receive nebulized AP-003 or identical placebo twice daily during 10 days.

开始日期2021-09-15

申办/合作机构

Pontificia Universidad Católica de Chile

[+1]

100 项与 Interferon alpha 2b inhalation (Altum Pharmaceuticals/BetterLife Pharma) 相关的临床结果

登录后查看更多信息

100 项与 Interferon alpha 2b inhalation (Altum Pharmaceuticals/BetterLife Pharma) 相关的转化医学

登录后查看更多信息

100 项与 Interferon alpha 2b inhalation (Altum Pharmaceuticals/BetterLife Pharma) 相关的专利（医药）

登录后查看更多信息

项与 Interferon alpha 2b inhalation (Altum Pharmaceuticals/BetterLife Pharma) 相关的文献（医药）

2019-05-01·Applied biochemistry and biotechnology3区 · 工程技术

Molecular and Biological Characterization of a Prepared Recombinant Human Interferon Alpha 2b Isoform

3区 · 工程技术

Article

作者: El-Dabaa, Ehab ; Samir, Safia ; El-Sayed, Wael M ; Shaaban, Rasha

Recombinant human interferon alpha2b (rhIFN-α2b) protein is FDA approved for treatment of many tumors and viral diseases. A rhIFN-α2b isoform has been produced and purified from the refolding reaction using high-resolution anion ion exchange chromatography. This isoform has a proper MW (19 kDa) and high purity and homogeneity. The conservation of native linear and conformational epitopes in this isoform was immunologically confirmed by Western blot and ELISA. Mass spectrometry assessment of its intact mass showed average mass (19,337 Da) equivalent to that of the expressed rhIFN-α2b protein without any chemical modification and without the first methionine. Peptide mapping of rhIFN-α2b through tryptic digestion of reductive/alkylated protein using urea as a denaturing agent gave the best pattern. The rhIFN-α2b had a high specific antiviral activity (2.5 × 10⁸ ± 1.1 × 10⁸IU/mg protein). In vivo clearance study of rhIFN-α2b in female SD rats (500 μg/kg, intramuscularly) revealed rapid clearance (elimination half-life 0.54 h with a maximum plasma concentration of 33,792 pg/ml) compared with the commercial rhIFN-α2 (elimination half-life 0.75-0.96 h). In conclusion, the prepared rhIFN-α2b isoform has high purity, homogeneity, native like chemical and structural composition, high antiviral activity, and proper biological stability, which reduce its immunogenicity and raise its therapeutic efficiency.

2011-04-01·Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi

[A novel recombinant human interferon alpha2b with high antivirus activity by combinatorial mutagenesis].

Article

作者: Du, Lei ; Zhao, Guangrong ; Zhu, Linqi

In order to create a novel recombinant human interferon alpha2b (rh-IFN alpha2b) with higher biological activity, we subjected the rational designed sequence of rh-IFN alpha2b to direct evolution by strategy of the combinatorial mutagenesis. The amino acid residues at multiple sites of 52-53-55, 103-107, and 121-125 were simultaneously mutated. The resulted gene of the mutated rh-IFN a2b was cloned into the pET28a and expressed in E. coli BL21 Condon plus (RIL). The anti-virus activity of the novel interferon alpha2b was 9.3 x 10(7) IU/mg, 93 times higher than the wild type (1 x 10(6) IU/mg). The results showed that the multiple point mutation used in this study could effectively combine the site effects of rh-IFN alpha2b and increase its biological activity.

2007-03-01·International journal of clinical pharmacology and therapeutics4区 · 医学

Transgenic avian-derived recombinant human interferon-a2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study

4区 · 医学

Article

作者: Pequignot, E. ; Kraft, W. K. ; Leavitt, M. C. ; Patel, T. B. ; Greenberg, H. E. ; Parker, S. H.

BACKGROUND/AIMS:

This study characterized the safety and pharmacological properties of AVI-005, a novel glycosylated recombinant human interferon-alpha2b produced from the egg whites of chickens transfected with human cDNA.

METHODS:

18 healthy volunteers received single subcutaneous rising doses (0.5, 1.66 or 5 million international units, MIU) of AVI-005. A randomized parallel comparator group of 10 subjects received 5 MIU of unglycosylated IFN-alpha2b (Intron A). The pharmacokinetic parameters t1/2, tmax, Cmax, AUC0-24h, Vd, and clearance were compared between AVI-005 and unglycosylated IFN-alpa2b.

RESULTS:

At equipotent doses, AVI-005 had a larger AUC0-24h than the control interferon. Pharmacodynamic markers ofneopterin and beta2-microglobulin for the two treatments were similar. These markers were increased by AVI-005 in a dose-dependent manner. Pharmacodynamic responses to treatment with AVI-005 were shown by the change in mRNA expression for interferon inducible protein kinase and 2'5'-oligoadenylate synthetase. Adverse events in the two groups were qualitatively and quantitatively similar.

CONCLUSION:

AVI-005 demonstrates biological activity and pharmaco-kinetic properties in humans that support further development.

100 项与 Interferon alpha 2b inhalation (Altum Pharmaceuticals/BetterLife Pharma) 相关的药物交易

登录后查看更多信息